Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Conventional treatment options have limited efficacy because most cases are in the advanced stage at the time of diagnosis. In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meng-Jiao, He, Qing, Li, Mei, Luo, Feng, Guan, Yong-Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790503/
https://www.ncbi.nlm.nih.gov/pubmed/27022285
http://dx.doi.org/10.2147/OTT.S80635
_version_ 1782420998204686336
author Li, Meng-Jiao
He, Qing
Li, Mei
Luo, Feng
Guan, Yong-Song
author_facet Li, Meng-Jiao
He, Qing
Li, Mei
Luo, Feng
Guan, Yong-Song
author_sort Li, Meng-Jiao
collection PubMed
description Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Conventional treatment options have limited efficacy because most cases are in the advanced stage at the time of diagnosis. In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown its good antitumor activities in treating NSCLC in a number of studies. This paper reviews its role in the targeted treatment of NSCLC in Chinese patients.
format Online
Article
Text
id pubmed-4790503
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47905032016-03-28 Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients Li, Meng-Jiao He, Qing Li, Mei Luo, Feng Guan, Yong-Song Onco Targets Ther Review Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Conventional treatment options have limited efficacy because most cases are in the advanced stage at the time of diagnosis. In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown its good antitumor activities in treating NSCLC in a number of studies. This paper reviews its role in the targeted treatment of NSCLC in Chinese patients. Dove Medical Press 2016-03-09 /pmc/articles/PMC4790503/ /pubmed/27022285 http://dx.doi.org/10.2147/OTT.S80635 Text en © 2016 Li et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Li, Meng-Jiao
He, Qing
Li, Mei
Luo, Feng
Guan, Yong-Song
Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
title Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
title_full Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
title_fullStr Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
title_full_unstemmed Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
title_short Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
title_sort role of gefitinib in the targeted treatment of non-small-cell lung cancer in chinese patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790503/
https://www.ncbi.nlm.nih.gov/pubmed/27022285
http://dx.doi.org/10.2147/OTT.S80635
work_keys_str_mv AT limengjiao roleofgefitinibinthetargetedtreatmentofnonsmallcelllungcancerinchinesepatients
AT heqing roleofgefitinibinthetargetedtreatmentofnonsmallcelllungcancerinchinesepatients
AT limei roleofgefitinibinthetargetedtreatmentofnonsmallcelllungcancerinchinesepatients
AT luofeng roleofgefitinibinthetargetedtreatmentofnonsmallcelllungcancerinchinesepatients
AT guanyongsong roleofgefitinibinthetargetedtreatmentofnonsmallcelllungcancerinchinesepatients

Ejemplares similares